U.O. Ematologia Vito Fazzi Trials

U.O. Ematologia Vito Fazzi	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Renzo, Nicola Di

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

AMELIORATE, NCT04174612: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting

172

Europe

Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia With FLT3/ITD Mutation

12/22

08/25

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

ALL2418, NCT03610438 / 2018-003006-32: Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Recruiting

Europe

Inotuzumab Ozogamicin (IO)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoid Leukemia

11/22

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Active, not recruiting

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

11/24

RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting

Europe

RVU120, SEL120, Venetoclax

Ryvu Therapeutics SA

Acute Myeloid Leukemia

02/26

09/26

RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting

Europe, Canada

RVU120, SEL120

Ryvu Therapeutics SA

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome

02/26

09/26

PENTALLO, NCT03494959: Pentaglobin in CRE and PA Neutropenic Infections

Recruiting

120

Europe

Pentaglobin

Gruppo Italiano Trapianto di Midollo Osseo

Septic Shock

06/24

06/25

DARATALL-VHR, NCT06253637: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

Recruiting

Europe

Daratumumab plus chemotherapy according to the national treatment program

Gruppo Italiano Malattie EMatologiche dell'Adulto

T-Lymphocytic Leukemia, Acute

10/29

NCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting

Europe

Ponatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chemotherapy, Leukemia, Acute Lymphoblastic

02/25

07/28

IDIOME-STUDY, NCT03503409: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Active, not recruiting

Europe

AG-120

Groupe Francophone des Myelodysplasies

Myelodysplastic Syndromes, Acute Myeloid Leukemia

04/25

FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting

1/2

122

Europe

Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Relapsed or Refractory Hodgkin's Lymphoma

04/27

04/30

NCT01064557: "AIDA" Protocol (LAP 0493)

Recruiting

N/A

1068

Europe, RoW

all-trans retinoic acid (ATRA)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Leukemia

12/20

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting

N/A

104

Europe

Venetoclax plus HMA

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

12/22

12/23

ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting

N/A

190

Europe

acalabrutinib, Calquence

AstraZeneca, Yghea

Chronic Lymphocytic Leukemia

02/30

NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting

N/A

200

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

10/23

06/24

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting

N/A

237

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes

03/25

NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting

N/A

Europe

Dasatinib and blinatumomab

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoblastic Leukemia

05/24

NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

Recruiting

N/A

Europe

bone marrow and/or peripheral blood samples withdrawal

Gruppo Italiano Malattie EMatologiche dell'Adulto

T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All

05/24

CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting

N/A

520

Europe

Quality of life questionnaires

Gruppo Italiano Malattie EMatologiche dell'Adulto

Multiple Myeloma

12/24

NCT05934084: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Recruiting

N/A

552

Europe

Lifestyles Implemented-Survivorship Care Plan (LS-SCP)

Fondazione Italiana Linfomi - ETS

Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)

02/26



	Diseases Companies Products Productz Mechanisms of Action Sites